mirtazapine has been researched along with Pregnancy in 27 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo." | 9.34 | Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. ( Andersen, JT; Futtrup, TB; Jensen, AK; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2020) |
| "In this nationwide Danish register study, mirtazapine exposure in pregnancy was not associated with major congenital malformations, spontaneous abortion, stillbirth, or neonatal death." | 8.12 | Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study. ( Andersen, JT; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2022) |
| "This multicenter, observational prospective cohort study addresses the risk associated with exposure to mirtazapine during pregnancy." | 7.81 | Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. ( Arnon, J; Buclin, T; Clementi, M; Eleftheriou, G; Kaplan, YC; Klinger, G; Malm, H; Maňáková, E; Merlob, P; Panchaud, A; Pistelli, A; Rothuizen, LE; Stephens, S; Te Winkel, B; Winterfeld, U, 2015) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 7.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 7.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| "Here we present the case of a 30-year-old woman with type I diabetes mellitus, preeclampsia and treatment resistant persistent hyperemesis gravidarum in her 25th week of gestation who was successfully treated with the antidepressant mirtazapine (Remergil)." | 7.74 | Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine. ( Gembruch, U; Heep, A; Rohde, A; Schwarzer, V, 2008) |
| "Mirtazapine seems to be an effective treatment modality in patients with severe hyperemesis gravidarum who do not respond to conventional anti-emesis treatment regimens." | 7.73 | Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. ( Dogan, E; Gol, M; Guclu, S; Saygili, U, 2005) |
| " When the patient asked for termination of the pregnancy because of the unbearable symptoms, treatment with intravenous mirtazapine (Remergil) was started." | 7.72 | Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. ( Dembinski, J; Dorn, C; Rohde, A, 2003) |
| " One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo." | 5.34 | Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. ( Andersen, JT; Futtrup, TB; Jensen, AK; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2020) |
| "Mirtazapine is a novel piperazinoazepine antidepressant, unrelated to any known class of antidepressants." | 5.33 | Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. ( De Santis, M; Diav-Citrin, O; Djulus, J; Einarson, A; Einarson, TR; Kennedy, D; Koren, G; Shakir, S; Voyer Lavigne, S; Wilton, L, 2006) |
| "In this nationwide Danish register study, mirtazapine exposure in pregnancy was not associated with major congenital malformations, spontaneous abortion, stillbirth, or neonatal death." | 4.12 | Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study. ( Andersen, JT; Løkkegaard, ECL; Ostenfeld, A; Pedersen, LH; Petersen, TS; Westergaard, HB, 2022) |
| "To assess whether the use of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, mirtazapine, venlafaxine or other antidepressants is associated with late elective termination of pregnancy." | 3.81 | Use of antidepressants and association with elective termination of pregnancy: population based case-control study. ( Artama, M; Engeland, A; Furu, K; Gissler, M; Haglund, B; Kieler, H; Malm, H; Nørgaard, M; Stephansson, O; Valdimarsdottir, U; Zoega, H, 2015) |
| "This multicenter, observational prospective cohort study addresses the risk associated with exposure to mirtazapine during pregnancy." | 3.81 | Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. ( Arnon, J; Buclin, T; Clementi, M; Eleftheriou, G; Kaplan, YC; Klinger, G; Malm, H; Maňáková, E; Merlob, P; Panchaud, A; Pistelli, A; Rothuizen, LE; Stephens, S; Te Winkel, B; Winterfeld, U, 2015) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 3.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "Mirtazapine is a new antidepressant used in last years, however experience with it during pregnancy is unsatisfactory on the present." | 3.76 | Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test. ( Hubickova, L; Kostalova, J; Manakova, E; Zemanova, Z, 2010) |
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 3.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| "Here we present the case of a 30-year-old woman with type I diabetes mellitus, preeclampsia and treatment resistant persistent hyperemesis gravidarum in her 25th week of gestation who was successfully treated with the antidepressant mirtazapine (Remergil)." | 3.74 | Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine. ( Gembruch, U; Heep, A; Rohde, A; Schwarzer, V, 2008) |
| "Mirtazapine seems to be an effective treatment modality in patients with severe hyperemesis gravidarum who do not respond to conventional anti-emesis treatment regimens." | 3.73 | Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. ( Dogan, E; Gol, M; Guclu, S; Saygili, U, 2005) |
| " When the patient asked for termination of the pregnancy because of the unbearable symptoms, treatment with intravenous mirtazapine (Remergil) was started." | 3.72 | Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. ( Dembinski, J; Dorn, C; Rohde, A, 2003) |
| "Hyperemesis gravidarum is a diagnosis reserved for refractory cases of NVP and therefore by definition poses treatment challenges." | 2.66 | Management Considerations for Recalcitrant Hyperemesis. ( Dotters-Katz, S; Kuller, JA; Post, A; Spinosa, D, 2020) |
| "Mirtazapine-treated neuron-conditioned medium (Mir-NCM) induced astrocyte proliferation and upregulated MT expression via 5-HT1A receptors on astrocytes." | 1.56 | Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection. ( Asanuma, M; Kagawa, D; Kikuoka, R; Kitamura, Y; Kubota, N; Maeda, M; Miyazaki, I; Moriyama, M; Murakami, S; Sato, A; Sendo, T, 2020) |
| "Hyperemesis gravidarum is not uncommon." | 1.46 | Intractable hyperemesis gravidarum in a patient with type 1 diabetes. ( Arshad, MF; Bekhit, M; Javed, N, 2017) |
| "Mirtazapine was detected (1." | 1.34 | Transfer of the antidepressant mirtazapine into breast milk. ( Hackett, LP; Ilett, KF; Kohan, R; Kristensen, JH; Rampono, J, 2007) |
| "Mirtazapine is a novel piperazinoazepine antidepressant, unrelated to any known class of antidepressants." | 1.33 | Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. ( De Santis, M; Diav-Citrin, O; Djulus, J; Einarson, A; Einarson, TR; Kennedy, D; Koren, G; Shakir, S; Voyer Lavigne, S; Wilton, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Ostenfeld, A | 2 |
| Petersen, TS | 2 |
| Pedersen, LH | 3 |
| Westergaard, HB | 2 |
| Løkkegaard, ECL | 2 |
| Andersen, JT | 2 |
| Spinosa, D | 1 |
| Post, A | 1 |
| Kuller, JA | 1 |
| Dotters-Katz, S | 1 |
| Futtrup, TB | 1 |
| Jensen, AK | 1 |
| Kikuoka, R | 1 |
| Miyazaki, I | 1 |
| Kubota, N | 1 |
| Maeda, M | 1 |
| Kagawa, D | 1 |
| Moriyama, M | 1 |
| Sato, A | 1 |
| Murakami, S | 1 |
| Kitamura, Y | 1 |
| Sendo, T | 1 |
| Asanuma, M | 1 |
| Arshad, MF | 1 |
| Javed, N | 1 |
| Bekhit, M | 1 |
| Kjaersgaard, MI | 1 |
| Parner, ET | 1 |
| Vestergaard, M | 1 |
| Sørensen, MJ | 1 |
| Olsen, J | 1 |
| Christensen, J | 1 |
| Bech, BH | 1 |
| Kieler, H | 1 |
| Malm, H | 2 |
| Artama, M | 1 |
| Engeland, A | 1 |
| Furu, K | 1 |
| Gissler, M | 1 |
| Nørgaard, M | 1 |
| Stephansson, O | 1 |
| Valdimarsdottir, U | 1 |
| Zoega, H | 1 |
| Haglund, B | 1 |
| Smit, M | 2 |
| Wennink, H | 1 |
| Heres, M | 1 |
| Dolman, KM | 2 |
| Honig, A | 2 |
| Winterfeld, U | 1 |
| Klinger, G | 2 |
| Panchaud, A | 1 |
| Stephens, S | 1 |
| Arnon, J | 1 |
| Te Winkel, B | 1 |
| Clementi, M | 1 |
| Pistelli, A | 1 |
| Maňáková, E | 2 |
| Eleftheriou, G | 1 |
| Merlob, P | 2 |
| Kaplan, YC | 1 |
| Buclin, T | 1 |
| Rothuizen, LE | 1 |
| Gentile, S | 1 |
| Abramowitz, A | 1 |
| Miller, ES | 1 |
| Wisner, KL | 1 |
| Omay, O | 1 |
| Einarson, A | 2 |
| Sokolover, N | 1 |
| Hubickova, L | 1 |
| Kostalova, J | 1 |
| Zemanova, Z | 1 |
| Lieb, M | 1 |
| Palm, U | 1 |
| Jacoby, D | 1 |
| Baghai, TC | 1 |
| Severus, E | 1 |
| Uguz, F | 1 |
| Kesim, M | 2 |
| Yaris, F | 2 |
| Kadioglu, M | 2 |
| Yaris, E | 2 |
| Kalyoncu, NI | 2 |
| Ulku, C | 2 |
| Biswas, PN | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Rohde, A | 2 |
| Dembinski, J | 1 |
| Dorn, C | 1 |
| Unsal, M | 1 |
| Guclu, S | 1 |
| Gol, M | 1 |
| Dogan, E | 1 |
| Saygili, U | 1 |
| Djulus, J | 1 |
| Koren, G | 1 |
| Einarson, TR | 1 |
| Wilton, L | 1 |
| Shakir, S | 1 |
| Diav-Citrin, O | 1 |
| Kennedy, D | 1 |
| Voyer Lavigne, S | 1 |
| De Santis, M | 1 |
| Kristensen, JH | 1 |
| Ilett, KF | 1 |
| Rampono, J | 1 |
| Kohan, R | 1 |
| Hackett, LP | 1 |
| Klier, CM | 1 |
| Mossaheb, N | 1 |
| Lee, A | 1 |
| Zernig, G | 1 |
| Schwarzer, V | 1 |
| Heep, A | 1 |
| Gembruch, U | 1 |
| Lennestål, R | 1 |
| Källén, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Validating the Effect of Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum: A Double-Blind Randomised Placebo-Controlled Multicentre Trial[NCT03785691] | Phase 2 | 58 participants (Actual) | Interventional | 2019-03-01 | Terminated (stopped due to Recruiting difficulties) | ||
| Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)[NCT05452174] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2022-06-13 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mirtazapine and Pregnancy
| Article | Year |
|---|---|
Management Considerations for Recalcitrant Hyperemesis.
Topics: Adrenal Cortex Hormones; Diazepam; Disease Management; Enteral Nutrition; Female; Humans; Hyperemesi | 2020 |
Mirtazapine in pregnancy and lactation - A systematic review.
Topics: Antidepressive Agents, Tricyclic; Breast Feeding; Depressive Disorder; Female; Humans; Lactation; Mi | 2016 |
Treatment options for hyperemesis gravidarum.
Topics: Adrenergic alpha-Antagonists; Adult; Antiemetics; Dopamine Agonists; Female; Humans; Hyperemesis Gra | 2017 |
1 trial available for mirtazapine and Pregnancy
| Article | Year |
|---|---|
Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Mirtazapine; Multicenter Studies as Topic; Onda | 2020 |
23 other studies available for mirtazapine and Pregnancy
| Article | Year |
|---|---|
Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study.
Topics: Abortion, Spontaneous; Child; Cohort Studies; Female; Humans; Infant, Newborn; Mirtazapine; Perinata | 2022 |
Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection.
Topics: Animals; Antioxidants; Astrocytes; Cells, Cultured; Dopamine; Dopaminergic Neurons; Female; Male; Me | 2020 |
Intractable hyperemesis gravidarum in a patient with type 1 diabetes.
Topics: Antiemetics; Cesarean Section; Diabetes Mellitus, Type 1; Female; Gestational Age; Humans; Hyperemes | 2017 |
Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study.
Topics: Abortion, Spontaneous; Adult; Antidepressive Agents; Cyclohexanols; Depression; Duloxetine Hydrochlo | 2013 |
Use of antidepressants and association with elective termination of pregnancy: population based case-control study.
Topics: Abortion, Induced; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Case-Control Stud | 2015 |
Mirtazapine in pregnancy and lactation: data from a case series.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Tricyclic; Breast Feeding; Cohort Studies | 2015 |
Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents; Birth Weight; Case-Control Studies; Depre | 2015 |
Pharmacological management of borderline personality disorder in a pregnant woman with a previous history of alcohol addiction: a case report.
Topics: Adult; Alcoholism; Borderline Personality Disorder; Diagnosis, Dual (Psychiatry); Female; Humans; Mi | 2015 |
Is Mirtazapine an Effective Treatment for Nausea and Vomiting of Pregnancy?: A Case Series.
Topics: Adult; Antidepressive Agents; Female; Humans; Mirtazapine; Nausea; Pregnancy; Pregnancy Complication | 2017 |
Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Body Temperature Regulation; Female; Fol | 2008 |
Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test.
Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents, Tricyclic; Chick Embryo; Depression; Do | 2010 |
[Mirtazapine and hyperemesis gravidarum].
Topics: Adult; Antidepressive Agents, Tricyclic; Female; Humans; Hyperemesis Gravidarum; Mianserin; Mirtazap | 2012 |
Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Dose-Response Relationship, Drug; Feeding and E | 2013 |
Mirtazapine use in two pregnant women: is it safe?
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Depression; Drug Therapy, Combination; Female; Fol | 2002 |
The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tri | 2003 |
Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy.
Topics: Abortion, Induced; Adult; Antidepressive Agents, Tricyclic; Cesarean Section; Female; Humans; Hypere | 2003 |
Newer antidepressants in pregnancy: prospective outcome of a case series.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, | 2004 |
Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature.
Topics: Adult; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; Mianserin; Mirtazapine; | 2005 |
Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Abortion, Therapeutic; Adult; Antidepressive Age | 2006 |
Transfer of the antidepressant mirtazapine into breast milk.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Breast Feeding; Depressi | 2007 |
Mirtazapine and breastfeeding: maternal and infant plasma levels.
Topics: Adult; Antidepressive Agents, Tricyclic; Breast Feeding; Depressive Disorder; Female; Humans; Infant | 2007 |
Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Diabetes Mellitus, Type 1; Drug Resistance; Female; Humans; | 2008 |
Delivery outcome in relation to maternal use of some recently introduced antidepressants.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adrenergic Uptake Inhibitors; Antidepressive Age | 2007 |